Атеротромбоз (Jul 2016)

DURATION OF DUAL ANTIPLATELET THERAPY

  • O. L. Barbarash

DOI
https://doi.org/10.21518/2307-1109-2016-1-59-68
Journal volume & issue
Vol. 0, no. 1
pp. 59 – 68

Abstract

Read online

The review article updates on the key challenge in the present-day cardiology duration of dual antiplatelet therapy (DAPT) in patients with a history of acute coronary syndrome. The relevant clinical guidelines are analyzed, and results of the recent clinical trials and meta-analyses are highlighted. A risk assessment scale for evaluating ischemic and bleeding risks based on the study of DAPT is presented.

Keywords